Merck’s Winrevair: A Catalyst for Stock Growth Amid Promising Clinical Developments
In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
Healio13h
Winrevair PAH trial stopped due to earlier ‘robust evidence’
Please provide your email address to receive an email when new articles are posted on . The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension ...
The Pharma Letter1d
The week in pharma: action, reaction and insight – week to January 31
Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...
Zacks.com on MSN2d
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
appliedclinicaltrialsonline2d
Kazia Therapeutics Launches Clinical Trial Evaluating Paxalisib in Combination with Keytruda or Lynparza for the Treatment of Advanced Breast Cancer
John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...
Pulmonaryhypertensionnews.com2d
Early Winrevair trial end to allow all patients to start active treatment
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
Daily3d
Merck to stop trial evaluating Winrevair early in pulmonary arterial hypertension
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
Pharmabiz3d
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...
Managed Healthcare Executive3d
2025 Digital Healthcare Outlook: Compliance, Security and Collaboration
Some regulatory changes are already set to happen this year, but reduced regulation under the new administration could have a ...
MSD halts Winrevair trial due to success of previous study
MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...
Monthly Prescribing Reference3d
Sotatercept Trial Ends Due to Positive Clinical Program Efficacy Data
A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
Managed Healthcare Executive3d
Another Trial of Winrevair Stopped Early Due to Positive Efficacy
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.